Limits...
Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.

Shao J, Li Y, Zhao P, Yue X, Jiang J, Liang X, He X - PLoS ONE (2014)

Bottom Line: However, inconsistent results have been reported.In conclusion, this meta-analysis indicated the common polymorphisms in mTOR gene might be genetic risk factors for the carcinogenesis and clinical outcomes of cancer patients.However, further investigation on large population and different ethnicities are warranted.

View Article: PubMed Central - PubMed

Affiliation: Department of CT/MRI, Wuhan Children's Hospital, Hubei, China.

ABSTRACT
Genetic polymorphisms in mTOR gene may be associated with cancer risk and clinical outcomes of cancer patients by affecting mTOR gene expression or its activation. However, inconsistent results have been reported. The aim of this study is to systematically evaluate the association between mTOR polymorphisms (rs2295080, rs2536 and rs11121704) and cancer risk as well as clinical outcome by a meta-analysis. We identified 10 eligible studies and extracted data by two investigators. Based on dominant and recessive models, odds ratio (ORs) and 95% confidence intervals (CIs) were calculated by using Stata, version 11 to evaluate the association strength. Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy. However, rs2536 may not influence cancer susceptibility. In conclusion, this meta-analysis indicated the common polymorphisms in mTOR gene might be genetic risk factors for the carcinogenesis and clinical outcomes of cancer patients. However, further investigation on large population and different ethnicities are warranted.

Show MeSH

Related in: MedlinePlus

Forest plots of clinical outcomes with the mTOR rs2529080 and rs11121704 polymorphisms under the recessive model.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4016248&req=5

pone-0097085-g003: Forest plots of clinical outcomes with the mTOR rs2529080 and rs11121704 polymorphisms under the recessive model.

Mentions: Overall, our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12–1.36, p<0.0005) (Fig. 2) but not with clinical outcomes (Fig. 3), while the TT genotype of rs11121704 were associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01–2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy (Fig. 3). However, rs2536 was not associated with cancer risk under both dominant and recessive models (Fig. 2).


Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.

Shao J, Li Y, Zhao P, Yue X, Jiang J, Liang X, He X - PLoS ONE (2014)

Forest plots of clinical outcomes with the mTOR rs2529080 and rs11121704 polymorphisms under the recessive model.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4016248&req=5

pone-0097085-g003: Forest plots of clinical outcomes with the mTOR rs2529080 and rs11121704 polymorphisms under the recessive model.
Mentions: Overall, our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12–1.36, p<0.0005) (Fig. 2) but not with clinical outcomes (Fig. 3), while the TT genotype of rs11121704 were associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01–2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy (Fig. 3). However, rs2536 was not associated with cancer risk under both dominant and recessive models (Fig. 2).

Bottom Line: However, inconsistent results have been reported.In conclusion, this meta-analysis indicated the common polymorphisms in mTOR gene might be genetic risk factors for the carcinogenesis and clinical outcomes of cancer patients.However, further investigation on large population and different ethnicities are warranted.

View Article: PubMed Central - PubMed

Affiliation: Department of CT/MRI, Wuhan Children's Hospital, Hubei, China.

ABSTRACT
Genetic polymorphisms in mTOR gene may be associated with cancer risk and clinical outcomes of cancer patients by affecting mTOR gene expression or its activation. However, inconsistent results have been reported. The aim of this study is to systematically evaluate the association between mTOR polymorphisms (rs2295080, rs2536 and rs11121704) and cancer risk as well as clinical outcome by a meta-analysis. We identified 10 eligible studies and extracted data by two investigators. Based on dominant and recessive models, odds ratio (ORs) and 95% confidence intervals (CIs) were calculated by using Stata, version 11 to evaluate the association strength. Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy. However, rs2536 may not influence cancer susceptibility. In conclusion, this meta-analysis indicated the common polymorphisms in mTOR gene might be genetic risk factors for the carcinogenesis and clinical outcomes of cancer patients. However, further investigation on large population and different ethnicities are warranted.

Show MeSH
Related in: MedlinePlus